

The new bronchopulmonary dysplasia

Alan H. Jobe

Cincinnati Children's Hospital, Division of Pulmonary Biology, University of Cincinnati, Cincinnati, Ohio, USA

Correspondence to Alan H. Jobe, MD, PhD, Division of Pulmonary Biology, Cincinnati Children's Hospital, ML#7029, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA

Tel: +1 513 636 8563; fax: +1 513 636 8691; e-mail: alan.jobe@cchmc.org

Current Opinion in Pediatrics 2011, 23:167–172

Purpose of review

Bronchopulmonary dysplasia (BPD) remains the most common severe complication of preterm birth. A number of recent animal models and clinical studies provide new information about pathophysiology and treatment.

Recent findings

The epidemiology of BPD continues to demonstrate that birth weight and gestational age are most predictive of BPD. Correlations of BPD with chorioamnionitis are clouded by the complexity of the fetal exposures to inflammation. Excessive oxygen use in preterm infants can increase the risk of BPD but low saturation targets may increase death. Numerous recent trials demonstrate that many preterm infants can be initially stabilized after delivery with continuous positive airway response (CPAP) and then be selectively treated with surfactant for respiratory distress syndrome. The growth of the lungs of the infant with BPD through childhood remains poorly characterized.

Summary

Recent experiences in neonatology suggest that combining less invasive care strategies that avoid excessive oxygen and ventilation, decrease postnatal infections, and optimize nutrition may decrease the incidence and severity of BPD.

Keywords

lung injury, oxygen, prematurity, ventilation

Curr Opin Pediatr 23:167–172
© 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins
1040-8703

Introduction

Bronchopulmonary dysplasia (BPD) remains the most common complication of very preterm birth. New research published within the last 2 years provides new insights into the pathophysiology of BPD, primarily using animal models. New clinical trials have not provided the clinician with new treatment strategies, but do provide some guidance. The National Heart, Lung and Blood Institute recently funded grants to explore childhood outcomes of lung diseases in infants and has established a five-center consortium to better characterize BPD and to identify useful biomarkers of disease progression. These research programs should benefit very preterm infants in the future.

Epidemiology of bronchopulmonary dysplasia

New information about populations of infants with BPD has appeared. Stroustrup and Trasande [1] report the incidence and resource use of infants with BPD, using a US nationwide database. They conclude that the incidence of BPD decreased by 4.3% per year for the years 1993–2006. There was an associated increase in noninvasive ventilation, but costs and length of hospitalizations for infants with BPD increased. We also learned more about the pattern of disease progression from the initial

14 days of oxygen exposure for 1340 infants born at 23–27 weeks' gestational age in 2002–2004 [2•] (Table 1). By multivariate analyses, the major predictors of BPD were not surprising: lower gestational age and mechanical ventilation on day 7. However, 33% of the persistent lung disease population (receiving 49% oxygen and 84% ventilated at 14 days) did not develop BPD, whereas 17% of the infants in room air at 14 days of age developed BPD. BPD is multifactorial in causality and our abilities to identify infants at risk are imperfect. I am surprised that 81% of this population was receiving conventional or high frequency ventilation at 7 days of age, suggesting that the investigators did not subscribe to noninvasive ventilatory support strategies. In a second report, these investigators identify fetal growth restriction in infants at 23–27 weeks' gestation as a risk factor for BPD [3].

The National Institutes of Child Health – Neonatal Research Network also has provided us with information on 9575 infants of 22–28 weeks gestation born from 2003 to 2007 [4••]. The incidence of BPD did not decrease over the 5 years in this population of well studied infants. The BPD outcomes are categorized for each gestational age according to the 2000 classification of BPD as mild (oxygen use for 28 days), moderate (oxygen need at 36 weeks), or severe (ventilatory support at 36 weeks)

Table 1 Clinical characteristics of 1346 infants grouped by patterns of lung disease to 14 days of age

	Consistently low FiO ₂	Pulmonary deterioration	Persistent lung disease
N	249	484	576
Percentage of population	20	38	43
Any chorioamnionitis (%)	55	54	53
Initial FiO ₂	0.25	0.29	0.38
FiO ₂ – 7 day	0.22	0.28	0.42
FiO ₂ – 14 day	0.21	0.40	0.49
Surfactant treatment (%)	78	89	97
CPAP – 7 day (%)	50	30	10*
Mechanical ventilation – 7 day (%)	21	57	84*
No PDA (%)	52	36	28*
BPD (%)	17	51	67*

BPD, bronchopulmonary dysplasia; FiO₂, fractional inspired oxygen concentration; PDA, patent ductus arteriosus. Data abstracted from [2*].

* $P < 0.001$ for trend across groups.


(Fig. 1). These curves are a useful visual reminder of the very high risk for severe BPD at the earliest gestational ages. However, overall, the numbers of infants with severe persistent BPD have decreased.

Chorioamnionitis and bronchopulmonary dysplasia

The clinical research on relationships between antenatal infection (chorioamnionitis) and respiratory distress syndrome (RDS) or BPD remains unsettled. Chorioamnionitis induced in sheep by pro-inflammatory mediators such as *Escherichia coli* lipopolysaccharide, IL-1, or live *Ureaplasma* induce both lung maturation and a phenotype of fetal lung inflammation [5]. Chorioamnionitis in fetal mice stimulates angiogenesis and an inflammatory profile comparable to the inflamed lungs of infants developing BPD [6]. The infants in the extremely low gestational age newborn study - acronym for a clinical study had extensive evaluations for histologic chorioamnionitis; and just

more than 50% were exposed to chorioamnionitis, but there was no correlation of chorioamnionitis with severity of early respiratory disease or BPD [2*] (Table 1). A multicenter study from the Canadian Neonatal Network found that clinical chorioamnionitis was associated with increased risks for intraventricular hemorrhage and early-onset sepsis, but not respiratory outcomes [7]. The simple associations of chorioamnionitis with RDS and BPD are confounded by the unknowns – duration of fetal exposure, extent of fetal responses, and the organisms inciting the responses, factors that are important based on animal model literature [5]. Clinical examples of the complexity of the relationships were provided by Been *et al.* [8*,9]. Chorioamnionitis isolated to the placenta and chorion was associated with decreased RDS, whereas chorioamnionitis with fetal involvement increased the risk of RDS in early gestational age infants [9]. Infants exposed to severe chorioamnionitis had decreased clinical responses to surfactant treatment, and those less favorable responses correlated with longer mechanical ventilation and more BPD [8*]. Thus, simple evaluations of a clinical or histologic diagnosis of chorioamnionitis may mask populations of infants at either increased or decreased risks of outcomes such as RDS and BPD. The future will be in the use of molecular microbiological techniques to better characterize the organisms causing fetal exposures and to better define the fetal or newborn responses. An example is the report by Payne *et al.* [10] demonstrating that the presence of *Ureaplasma parvum* in tracheal aspirates increased the odds ratio for BPD or death by 4.8.

Figure 1 Percentage of population of 9575 infants categorized as to severity of BPD based on the 2000 NIH conference definition



Sixty-eight percent of these infants had BPD. Severity of BPD decreased as gestational age increased. BPD, bronchopulmonary dysplasia. Data abstracted from [4**].

Inhaled nitric oxide

The use of inhaled nitric oxide (iNO) to prevent BPD remains controversial. A new large trial demonstrated that the early use of low-dose iNO had no beneficial effects [11]. The National Institutes of Health (NIH) held a Consensus Conference on iNO for preterm infants in the fall of 2010, which did not recommend routine use of iNO for preterm infants at risk of BPD [12**]. Research on how iNO treatments might help preterm infants is continuing.

McCurnin and colleagues [13] demonstrated in preterm baboons that postnatal estriol supplementation improved pulmonary outcomes, possibly by upregulating nitric oxide synthase. iNO decreases the alveolar and vascular growth abnormalities induced by oxygen exposure of newborn rodents. iNO also will blunt the lung structural abnormalities and pulmonary hypertension caused by bleomycin in newborn rats [14]. Vadivel *et al.* [15] mitigated the oxygen-induced alveolar arrest in newborn rats with supplementation of L-citrulline, a precursor of NO. The animal data strongly support a protective role of iNO for injury of the saccular lung. The clinical challenge remains to develop treatment strategies that provide enough benefit to justify the cost of iNO or to identify other drugs to increase NO in the lung.

Oxygen use and bronchopulmonary dysplasia

Chronic exposure of the developing rodent lung to high oxygen concentrations uniformly causes structural changes similar to the new BPD. Chronic exposure of infants who need oxygen after 32 weeks to a higher oxygen saturation range will increase the incidence of BPD [16]. Depressed term infants can be resuscitated as effectively with room air as with supplemental oxygen, but preterm infants are different. Preterm infants born at 24–28 weeks gestation and in need of ventilatory support at delivery were initially resuscitated with 30 or 90% oxygen by Vento *et al.* [17[•]]. Oxygen exposures were adjusted to saturation targets of 75% at 5 min and 85% at 10 min. Heart rate responses were comparable and both groups received about 50% oxygen by 5 min and 30% oxygen by 10 min. The increased oxygen exposure for infants started at 90% oxygen from birth to 5 min of age correlated with more ventilatory support and a significant increase in BPD. Those infants with BPD had higher indicators of oxidant injury in blood and urine. This provocative report suggests that brief exposures of very preterm infants to high oxygen concentrations can initiate a lung injury resulting in BPD, despite comparable blood oxygen saturations over the period of resuscitation. The take home message for now is that resuscitation of very preterm infants should be initiated with 30–50% oxygen. These results need to be replicated.

A National Institute of Child Health and Development (NICHD)-Neonatal Research Network trial randomized infants of 24–27 weeks' gestation from Neonatal Intensive Care Unit (NICU) admission to 36 weeks to oxygen saturation targets of 85–89% or 91–95% [18^{••}]. The primary outcome for the trial was severe retinopathy of prematurity (ROP) or death, and the combined rates of severe ROP or death did not differ. However, in a classic demonstration of competing outcomes, the rate of death increased [relative risk 1.7, 95% confidence interval (CI) 1.01–1.60] and the rate of severe ROP decreased (relative

risk 0.52, 95% CI 0.37–0.73) with the lower saturation targets. BPD defined as oxygen use at 36 weeks also was decreased significantly for the population with the lower oxygen saturation target. These results, together with the Vento *et al.* report [17[•]], demonstrate how carefully oxygen exposures for very preterm infants may need to be regulated throughout the weeks of clinical management.

Ventilation and CPAP

As with oxygen exposure alone, mechanical ventilation alone can interfere with development of the saccular lung in animal models. Mokres *et al.* [19] demonstrate that ventilation of newborn mice with room air for 24 h induced apoptosis, disrupted alveolar septation, and inhibited angiogenesis. Recent clinical research has explored strategies to decrease ventilation-mediated injury or to avoid mechanical ventilation entirely. A meta-analysis of individual patient data from 10 randomized controlled trials demonstrates no benefit from high frequency ventilation relative to conventional ventilation for BPD or other adverse outcomes [20]. Either approach to ventilatory support is effective, but avoidance of mechanical ventilation is the best strategy in theory. A number of studies give the clinician guidance as to how that can be done in practice. The same 1316 infants who were randomized to oxygen saturation ranges in the NICHD trial [18^{••}] were also randomized prior to birth to intubation at delivery and surfactant treatment within 1 h of birth or to CPAP at delivery and surfactant as clinically indicated [21^{••}]. The protocol specified early extubation when possible. Although there was no difference in the primary outcome of BPD or death, most of the respiratory indicators favored the CPAP group (Table 2). The large decrease in use of postnatal corticosteroids with CPAP is particularly interesting with respect to the new policy statement from the American Academy of Pediatrics that recommends caution for the use of postnatal corticosteroids for BPD [22[•]]. This trial randomized infants prior to birth such that it included both depressed and more healthy infants. The recent COIN trial randomized only infants requiring some ventilatory assistance at 5 min of age to CPAP or intubation, which excluded the depressed and 'normal' infants [23]. Most of the respiratory outcomes favored CPAP in the COIN trial.

A trial from the Vermont–Oxford Network randomized infants to three groups: intubation, surfactant, and ventilation; intubation, surfactant, and extubation to CPAP; and CPAP with selective surfactant treatment [24]. The outcomes of death or BPD were not different between groups, but qualitatively favored the CPAP groups. Only 46% of the CPAP and selective surfactant group were ventilated over the first 7 days vs. 99% of the ventilation group. Other groups evaluated other wrinkles to the general theme of how to avoid mechanical ventilation

Table 2 Outcomes for early CPAP vs. intubation and surfactant

	Early CPAP	Intubation and surfactant	P
N	663	653	
Gestational age (weeks)	26.2 ± 1.1	26.2 ± 1.1	
Death or BPD (%)	47.8	51.0	0.30
Death (%)	14.2	17.5	0.09
BPD – O ₂ use at 36 weeks (%)	48.7	54.1	0.07
Mechanical ventilation (days, median)	10	13	0.03
Survival without mechanical ventilation (%)	55.3	48.8	0.01
Any air leak (%)	6.8	7.4	0.56
Postnatal steroids for BPD (%)	7.2	13.2	<0.01

BPD, bronchopulmonary dysplasia. Data abstracted from [21**].

while using surfactant. Sandri *et al.* [25] randomized 208 infants at birth with gestational ages of 25–28 weeks to either intubation within 30 min of birth, surfactant and extubation within 1 h to CPAP, or CPAP with selective surfactant treatment. These infants did not require intubation following delivery and were initially stabilized with CPAP if needed. Fifty-one percent of the selective surfactant group received surfactant. There were no differences in the need for mechanical ventilation within 5 days of age or in any other outcome. In contrast, Rojas *et al.* [26] randomized infants of 27–31 weeks gestation who were receiving CPAP to surfactant treatment within 1 h of birth and a return to CPAP or CPAP alone, with the primary outcome being need for mechanical ventilation. The subsequent need for mechanical ventilation was lower with surfactant treatment and CPAP (26%) than with CPAP alone (39%). Air leaks also were lower in the surfactant treatment groups, but other outcomes were not different. Another approach developed in Cologne, Germany is to support infants with CPAP and treat with surfactant via a fine feeding tube briefly placed into the trachea under direct vision, thus avoiding intubation [27,28]. In a randomized study, this gentle approach to surfactant treatment decreased the need for mechanical ventilation and decreased BPD [28].

Taken together, a strategy of early use of CPAP with surfactant treatment as clinically indicated is not worse than, and in most studies is marginally better than, routine intubation and surfactant treatment for very pre-term infants. Strategies for respiratory support of these tiny infants are not easily adapted to a practice guideline. In the delivery room, individual assessment (clinical judgment) will determine the intervention selected. Each infant should be continually assessed and given just the extra support needed, and CPAP may be sufficient for the majority of these infants for transition out of the delivery room. The decision about whom to treat with surfactant, and how, remains to be refined, but the accumulating evidence supports surfactant treatment as soon as the infant has ‘significant RDS’. For me, ‘significant’ means a chest film consistent with RDS, an increased work of breathing as assessed clinically, and an oxygen requirement of about 35% and rising.

Treatment of such infants early in their clinical course should decrease symptoms, decrease oxygen exposure, decrease air leaks, and shorten the clinical course.

The innovations to decrease BPD are new ways to give surfactant and more effective methods to deliver CPAP or noninvasive ventilation. Aerosolization of surfactant is an old idea that is again being evaluated [29]. Synchronized nasal ventilation avoids the endotracheal tube and can support infants with apnea [30,31]. Neural adjusted ventilatory assist (NAVA) is a technique for timing and modulating mechanical ventilation cycles using the electrical signal from the diaphragm detected with a fine catheter in the distal esophagus. NAVA is being evaluated for noninvasive ventilation of infants [32*]. Diblasi *et al.* [33] recently reported that a change in configuration of the pressure controller for bubble CPAP can strikingly increase the ability of bubble CPAP to assist ventilation in animal models. A package of individualized interventions to support ventilation, minimize oxygen exposure, minimize apnea, and encourage growth should decrease both the frequency and severity of BPD, but this disease will not go away.

Stem cells

The lung injury that is BPD is complex as it involves epithelial surfaces, the lung matrix, and the microvasculature. A dream for the future has been the concept of replacing injured cells with multipotent stem cells to ‘repopulate and regrow’ the BPD lung. There are a number of reports that demonstrate that stem cell treatments can mitigate oxidant injury in the developing rodent lung. Van Haaften *et al.* [34] gave bone marrow-derived mesenchymal stem cells by intratracheal injection to oxygen exposed newborn rats and found increased survival and improved exercise tolerance with less lung injury. However, few of the cells engrafted, and conditioned media from the cells blunted cell injury *in vitro*. Aslam *et al.* [35] gave newborn mice intravascular injections with bone marrow-derived mesenchymal stem cells and found protection from oxygen, but with minimal engraftment of cells in the lungs. The conditioned medium from the cells was as protective as the cells. Stem cell therapy in infants

would be difficult, but the identification of products from stem cells that blunt the injury progression in BPD has real potential. The good news is that perhaps the stem cells are not required, just their secreted products.

There is also new information about stem cells from infants that will help frame questions about these therapeutic approaches. Baker *et al.* [36] isolated endothelial colony-forming cells from cord blood of preterm infants and term infants. The cells from the preterm infants were recovered in higher numbers but were more sensitive to oxygen *in vitro* than cells from term infants. Borghesi *et al.* [37] reported that these same endothelial progenitor cells were in lower numbers in cord blood of preterm infants who subsequently developed BPD. These observations in infants at risk of BPD are starting points for recovery of stem cells from infants for growth *in vitro* for treatment with those cells or media from those cells.

Lung function in childhood and beyond

Major questions linger as to how the BPD lung grows through childhood and ages. We do not have definitive answers but several reports move these questions forward. Fakhoury *et al.* [38] measured lung function sequentially at 6, 12, and 24 months after NICU discharge in children with moderate to severe BPD and found that the abnormalities persisted without improvement. Filippone *et al.* [39] extended the observations to 9 and 15 years for infants with BPD who had lung functional abnormalities at 2 years of age. The 2-year-old children with significant airflow obstruction continued to have comparable findings in late childhood. Lung function also was assessed using spirometry at 11 years for infants born at less than 26 weeks' gestation [40^{••}]. This population of children had more chest deformities, more asthma, and more respiratory symptoms than did classmates born at term. Spirometry demonstrated airflow limitations that were most abnormal in the children with a history of BPD. A limitation of the traditional measurements of lung function in infants and children is that the measurements assess primarily small airway function. However, BPD causes decreased alveolar and vascular development – abnormalities of the distal lung parenchyma. Balinotti *et al.* [41] combined physiological techniques to measure alveolar gas volume with measurements of carbon monoxide diffusion to evaluate lung parenchymal growth in normal children in the first 2 years of life. They found that gas diffusion increased proportionately to alveolar volume, suggesting that alveolar numbers were increasing. They then applied these measurement techniques to children who had BPD and found decreased gas diffusion capacities, but normal alveolar gas volumes, suggesting a persistence of impaired alveolar development at 1 year of age [42^{••}]. These measurements provide the first functional measurements of the distal lung in children with BPD.

Conclusion

This review is a selective sampling of progress in the understanding and treatment of BPD. The controversy of management of the patent ductus arteriosus was not addressed [43]. An area of intense interest in BPD is the development of biomarkers for disease progression [44,45]. Ultimately, a decrease in BPD will depend not only on new information, but also on applications of packages of interventions that each may contribute to decreasing the severity and incidence of BPD [46,47]. My preferred practices are efforts to decrease the invasive nature of NICU care in general while empowering the very preterm infant to breathe spontaneously and grow. Such practices include transitioning infants from the delivery room with CPAP, early extubation for intubated infants, minimizing oxygen exposures and vascular catheters, and maximizing enteral nutrition.

Acknowledgements

This work was funded in part by grants HL97064 and HL101800 from the US National Institutes of Health and Human Development.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 255–256).

- 1 Stroustrup A, Trasande L. Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993–2006. *Pediatrics* 2010; 126:291–297.
- 2 Laughon M, Allred EN, Bose C, *et al.* Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. *Pediatrics* 2009; 123:1124–1131.
- A nice demonstration of the variable outcomes resulting from a 14-day history of oxygen exposure.
- 3 Bose C, Van Marter LJ, Laughon M, *et al.* Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. *Pediatrics* 2009; 124:e450–e458.
- 4 Stoll BJ, Hansen NI, Bell EF, *et al.* Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. *Pediatrics* 2010; 126:443–456.
- Recent epidemiology of outcomes of large numbers of very low birth weight infants.
- 5 Kramer BW, Kallapur S, Newnham J, Jobe AH. Prenatal inflammation and lung development. *Semin Fetal Neonatal Med* 2009; 14:2–7.
- 6 Miller JD, Benjamin JT, Kelly DR, *et al.* Chorioamnionitis stimulates angiogenesis in saccular stage fetal lungs via CC chemokines. *Am J Physiol Lung Cell Mol Physiol* 2010; 298:637–645.
- 7 Soraisham AS, Singhal N, McMillan DD, *et al.* A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. *Am J Obstet Gynecol* 2009; 200:372 e371–376 e371.
- 8 Been JV, Rours IG, Kornelisse RF, *et al.* Chorioamnionitis alters the response to surfactant in preterm infants. *J Pediatr* 2010; 156:10.e11–15.e11.
- A demonstration of the complex relationships between chorioamnionitis and outcomes such as RDS and BPD, using surfactant responses to evaluate lung disease.
- 9 Been JV, Rours IG, Kornelisse RF, *et al.* Histologic chorioamnionitis, fetal involvement, and antenatal steroids: effects on neonatal outcome in preterm infants. *Am J Obstet Gynecol* 2009; 201:587 e581–588 e581.
- 10 Payne MS, Goss KC, Connett GJ, *et al.* Molecular microbiological characterization of preterm neonates at risk of bronchopulmonary dysplasia. *Pediatr Res* 2010; 67:412–418.

- 11 Mercier JC, Hummler H, Durmeyer X, *et al.* Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. *Lancet* 2010; 376:346–354.
- 12 NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy for
 •• Preterm Infants, 27–29 October 2010.
 Recommendations from a nonbiased NIH panel that iNO should not be used routinely for preterm infants.
- 13 McCurmin DC, Pierce RA, Willis BC, *et al.* Postnatal estradiol up-regulates lung nitric oxide synthases and improves lung function in bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2009; 179:492–500.
- 14 Tourneux P, Markham N, Seedorf G, *et al.* Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats. *Am J Physiol Lung Cell Mol Physiol* 2009; 297:L1103–1111.
- 15 Vadivel A, Aschner JL, Rey-Parra GJ, *et al.* L-Citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats. *Pediatr Res* 2010; 68:519–525
- 16 Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. *N Engl J Med* 2003; 349:959–967.
- 17 Vento M, Moro M, Escrig R, *et al.* Preterm resuscitation with low oxygen
 • causes less oxidative stress, inflammation, and chronic lung disease. *Pediatrics* 2009; 124:e439–e449.
 The study demonstrates that brief exposures to high levels of oxygen during resuscitation only can increase the risk of BPD.
- 18 Carlo WA, Finer NN, Walsh MC, *et al.* Target ranges of oxygen saturation in
 •• extremely preterm infants. *N Engl J Med* 2010; 362:1959–1969.
 A large RCT demonstrating that a low oxygen saturation target may decrease severe ROP and BPD, but may increase death – an example of competing outcomes in clinical trials.
- 19 Mokres LM, Parai K, Hilgendorff A, *et al.* Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice. *Am J Physiol Lung Cell Mol Physiol* 2010; 298:L23–L35.
- 20 Cools F, Askie LM, Offringa M, *et al.* Elective high-frequency oscillatory versus conventional ventilation in preterm infants: a systematic review and meta-analysis of individual patients' data. *Lancet* 2010; 375:2082–2091.
- 21 Finer NN, Carlo WA, Walsh MC, *et al.* Early CPAP versus surfactant in
 •• extremely preterm infants. *N Engl J Med* 2010; 362:1970–1979.
 A large RCT demonstrating comparability of intubation and surfactant treatment or CPAP with selective surfactant treatment for very preterm infants.
- 22 Watterberg KL and American Academy of Pediatrics Committee on Fetus and
 • Newborn. Policy Statement: postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. *Pediatrics* 2010; 126:800–808.
 A new statement of the risks and benefits of postnatal corticosteroids to treat infants at risk of BPD. This statement recommends caution but is more positive toward corticosteroids than the previous AAP statement.
- 23 Morley CJ, Davis PG, Doyle LW, *et al.* Nasal CPAP or intubation at birth for very preterm infants. *N Engl J Med* 2008; 358:700–708.
- 24 Dunn M, Kaempf J, de Klerk A, *et al.* Delivery room management of preterm infants at risk for respiratory distress syndrome (RDS). *Abstract-PAS* 2010:1670.1672.
- 25 Sandri F, Plavka R, Ancora G, *et al.* Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. *Pediatrics* 2010; 125:e1402–e1409.
- 26 Rojas MA, Lozano JM, Rojas MX, *et al.* Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. *Pediatrics* 2009; 123:137–142.
- 27 Kribs A, Pillekamp F, Hunseler C, *et al.* Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ≤ 27 weeks). *Paediatr Anaesth* 2007; 17:364–369.
- 28 Kribs A, Hartel C, Kattner E, *et al.* Surfactant without intubation in preterm infants with respiratory distress: first multicenter data. *Klin Padiatr* 2010; 222:13–17.
- 29 Finer NN, Merritt TA, Bernstein G, *et al.* An open label, pilot study of Aerosurf(R) combined with nCPAP to prevent RDS in preterm neonates. *J Aerosol Med Pulm Drug Deliv* 2010; 23:303–309.
- 30 Bhandari V, Finer NN, Ehrenkranz RA, *et al.* Synchronized nasal intermittent positive-pressure ventilation and neonatal outcomes. *Pediatrics* 2009; 124:517–526.
- 31 Bhandari V. Nasal intermittent positive pressure ventilation in the newborn: review of literature and evidence-based guidelines. *J Perinatol* 2010; 30:505–512.
- 32 Beck J, Reilly M, Grasselli G, *et al.* Patient-ventilator interaction during neurally
 • adjusted ventilatory assist in low birth weight infants. *Pediatr Res* 2009; 65:663–668.
 The possibility that noninvasive ventilation triggered by diaphragmatic electrical activity can be used in infants is very attractive.
- 33 Diblasi RM, Zignego JC, Tang DM, *et al.* Noninvasive respiratory support of juvenile rabbits by high-amplitude bubble continuous positive airway pressure. *Pediatr Res* 2010; 67:624–629.
- 34 Van Haaften T, Byrne R, Bonnet S, *et al.* Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. *Am J Respir Crit Care Med* 2009; 180:1131–1142.
- 35 Aslam M, Baveja R, Liang OD, *et al.* Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. *Am J Respir Crit Care Med* 2009; 180:1122–1130.
- 36 Baker CD, Ryan SL, Ingram DA, *et al.* Endothelial colony-forming cells from preterm infants are increased and more susceptible to hyperoxia. *Am J Respir Crit Care Med* 2009; 180:454–461.
- 37 Borghesi A, Massa M, Campanelli R, *et al.* Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2009; 180:540–546.
- 38 Fakhoury KF, Sellers C, Smith EO, *et al.* Serial measurements of lung function in a cohort of young children with bronchopulmonary dysplasia. *Pediatrics* 2010; 125:e1441–e1447.
- 39 Filippone M, Bonetto G, Cherubin E, *et al.* Childhood course of lung function in survivors of bronchopulmonary dysplasia. *JAMA* 2009; 302:1418–1420.
- 40 Fawke J, Lum S, Kirkby J, *et al.* Lung function and respiratory symptoms at
 •• 11 years in children born extremely preterm: the EPICure study. *Am J Respir Crit Care Med* 2010; 182:237–245.
 Extremely premature infants with BPD have fixed airway disease at 11 years of age – an ominous finding for lung function later in life.
- 41 Balinotti JE, Tiller CJ, Llapur CJ, *et al.* Growth of the lung parenchyma early in life. *Am J Respir Crit Care Med* 2009; 179:134–137.
- 42 Balinotti JE, Chakr VC, Tiller C, *et al.* Growth of lung parenchyma in infants and
 •• toddlers with chronic lung disease of infancy. *Am J Respir Crit Care Med* 2010; 181:1093–1097.
 This report used carbon monoxide diffusion to measure lung parenchymal abnormalities that suggest decreased alveolarization in infants with a history of BPD.
- 43 Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? *J Perinatol* 2010; 30:241–252.
- 44 Been JV, Debeer A, van Iwaarden JF, *et al.* Early alterations of growth factor patterns in bronchoalveolar lavage fluid from preterm infants developing bronchopulmonary dysplasia. *Pediatr Res* 2010; 67:83–89.
- 45 Aghai ZH, Saslow JG, Meniru C, *et al.* High-mobility group box-1 protein in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia and steroid therapy. *J Perinatol* 2010; 30:610–615.
- 46 Birenbaum HJ, Dentry A, Cirelli J, *et al.* Reduction in the incidence of chronic lung disease in very low birth weight infants: results of a quality improvement process in a tertiary level neonatal intensive care unit. *Pediatrics* 2009; 123:44–50.
- 47 Payne NR, Finkelstein MJ, Liu M, *et al.* NICU practices and outcomes associated with 9 years of quality improvement collaboratives. *Pediatrics* 2010; 125:437–446.